|
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - MSD |
|
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
|
Expert Testimony - Various Companies |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - MSD |
|
|
|
Stock and Other Ownership Interests - MSD |
|
|
No Relationships to Disclose |